Literature DB >> 10760525

Peroxisome proliferator-activated receptor activators modulate the osteoblastic maturation of MC3T3-E1 preosteoblasts.

S M Jackson1, L L Demer.   

Abstract

The reduced bone mineral density (BMD) observed in osteoporosis results, in part, from reduced activity of bone-forming osteoblasts. We examined the effect of peroxisome proliferator-activated receptor (PPAR) activators on MC3T3-E1 preosteoblast maturation. Activators of PPARalpha, delta and gamma induced alkaline phosphatase activity, matrix calcification and the expression of osteoblast genes as determined by reverse transcriptase-polymerase chain reaction. However, at relatively high concentrations of the specific PPARgamma ligands, ciglitazone and troglitazone, maturation was inhibited. PPARalpha, delta and gamma1 were expressed in MC3T3-E1 cells. PPARgamma1 mRNA and protein levels were induced early during osteoblastic maturation. We speculate that endogenous and pharmacological PPAR activators may affect BMD by modulating osteoblastic maturation.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10760525     DOI: 10.1016/s0014-5793(00)01372-7

Source DB:  PubMed          Journal:  FEBS Lett        ISSN: 0014-5793            Impact factor:   4.124


  21 in total

1.  Bezafibrate enhances proliferation and differentiation of osteoblastic MC3T3-E1 cells via AMPK and eNOS activation.

Authors:  Xing Zhong; Ling-ling Xiu; Guo-hong Wei; Yuan-yuan Liu; Lei Su; Xiao-pei Cao; Yan-bing Li; Hai-peng Xiao
Journal:  Acta Pharmacol Sin       Date:  2011-04-18       Impact factor: 6.150

Review 2.  Molecular mechanisms of mesenchymal stem cell differentiation towards osteoblasts.

Authors:  Maya Fakhry; Eva Hamade; Bassam Badran; René Buchet; David Magne
Journal:  World J Stem Cells       Date:  2013-10-26       Impact factor: 5.326

3.  Effects of pioglitazone and fenofibrate co-administration on bone biomechanics and histomorphometry in ovariectomized rats.

Authors:  Susan Y Smith; Rana Samadfam; Luc Chouinard; Malaika Awori; Agnes Bénardeau; Frieder Bauss; Robert E Guldberg; Elena Sebokova; Matthew B Wright
Journal:  J Bone Miner Metab       Date:  2014-12-23       Impact factor: 2.626

4.  Characterization of stem and progenitor cells in the dental pulp of erupted and unerupted murine molars.

Authors:  Anamaria Balic; H Leonardo Aguila; Melissa J Caimano; Victor P Francone; Mina Mina
Journal:  Bone       Date:  2010-02-26       Impact factor: 4.398

5.  Nuclear receptor profile in calvarial bone cells undergoing osteogenic versus adipogenic differentiation.

Authors:  Flavia Q Pirih; Rosette Abayahoudian; David Elashoff; Farhad Parhami; Jeanne M Nervina; Sotirios Tetradis
Journal:  J Cell Biochem       Date:  2008-12-01       Impact factor: 4.429

6.  A subset of osteoblasts expressing high endogenous levels of PPARgamma switches fate to adipocytes in the rat calvaria cell culture model.

Authors:  Yuji Yoshiko; Kiyoshi Oizumi; Takuro Hasegawa; Tomoko Minamizaki; Kazuo Tanne; Norihiko Maeda; Jane E Aubin
Journal:  PLoS One       Date:  2010-07-26       Impact factor: 3.240

7.  Osteoblast-targeted suppression of PPARγ increases osteogenesis through activation of mTOR signaling.

Authors:  Hongli Sun; Jin Koo Kim; Richard Mortensen; Lorraine P Mutyaba; Kurt D Hankenson; Paul H Krebsbach
Journal:  Stem Cells       Date:  2013-10       Impact factor: 6.277

Review 8.  Skeletal consequences of thiazolidinedione therapy.

Authors:  A Grey
Journal:  Osteoporos Int       Date:  2007-09-28       Impact factor: 4.507

9.  Fibrates as therapy for osteoarthritis and rheumatoid arthritis? A systematic review.

Authors:  Inge C M van Eekeren; Stefan Clockaerts; Yvonne M Bastiaansen-Jenniskens; Eric Lubberts; Jan A N Verhaar; Gerjo J V M van Osch; Sita M Bierma-Zeinstra
Journal:  Ther Adv Musculoskelet Dis       Date:  2013-02       Impact factor: 5.346

10.  Different skeletal effects of the peroxisome proliferator activated receptor (PPAR)alpha agonist fenofibrate and the PPARgamma agonist pioglitazone.

Authors:  Unni Syversen; Astrid K Stunes; Björn I Gustafsson; Karl J Obrant; Lars Nordsletten; Rolf Berge; Liv Thommesen; Janne E Reseland
Journal:  BMC Endocr Disord       Date:  2009-03-30       Impact factor: 2.763

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.